

Hybrid

AMMF 2022 EUROPEAN CHOLANGIOCARCINOMA CONFERENCE

11-13 May 2022

PROGRAMME



AMMF

THE CHOLANGIOCARCINOMA CHARITY

We aim to lead a revolution in oncology to redefine cancer care



Chairman's Welcome	3
Co-chairs Welcome	4-5
About AMMF	6-7
AMMF European Website	9
World Cholangiocarcinoma Day	11
Global Cholangiocarcinoma Alliance	11
Presenters	12-17
Programme	18-27
Poster Presentations 2022	28-29
Cholangiocarcinoma-UK	30
Acknowledgements	31

Disclaimer

AMMF's 2022 Hybrid European Cholangiocarcinoma Conference is an international hybrid event run by AMMF and provided to international Healthcare Professionals from around the world. Please note that any prescribing information which may be provided may vary depending on local approval in each country. For purposes of the conference, best efforts were undertaken by AMMF and conference sponsors to ensure compliance with ABPI guidelines, however, you should review your local prescribing information and consult directly with the local affiliate of the relevant company to address any questions.

If you are not a Healthcare Professional, please be aware that, to comply with international pharmaceutical guidelines, certain areas of the meeting platform and conference programme are intended for Healthcare Professionals only and clear guidance will be provided for these areas.

#AMMF2022

 facebook.com/CharityAMMF
 [charityammf](https://twitter.com/charityammf)  [charityammf](https://www.instagram.com/charityammf)



BASL Endorsed
AMMF's conference is a BASL endorsed event.



CPD Registered
AMMF's conference is CPD accredited. Registered delegates logging in on both days will be awarded **12hrs CPD**. A PD Certificate of Attendance will be sent after the event.

Molecular testing in cholangiocarcinoma

Learn about tests for faulty genes and how they can guide your treatment if you have bile duct cancer (cholangiocarcinoma)



Booklet available in print or to download from the AMMF website (ammf.org.uk)



Noel Corrigan
Chair of Trustees – AMMF

Dear Friends

It is my great pleasure to welcome you to AMMF's Hybrid 2022 European Cholangiocarcinoma Conference.

For the first time since the hiatus caused by the COVID pandemic, I am delighted to be able to welcome you both face-to-face and virtually, which I am sure will enable greater participation than ever. I would like to thank our co-chairs – Jesus Bañales and Juan Valle – for agreeing to keep things on track for us.

I am grateful to all AMMF's benefactors, many of whom are in attendance, without whose support this conference would not be possible, and who enable much of the work reported on here by our international community of researchers and practitioners. I extend a particular welcome to those patients, carers, family, and friends who are able to join us.

I am privileged to welcome you to the event that marks the 20th anniversary of the founding of the charity. In that time AMMF has grown in ways we could not have imagined, and you will hear more about how far we have come, and what has been achieved, as well as our plans. Over the course of three days there is something for everyone – patients and carers, practitioners, researchers, pharma: with updates from the UK, Europe and across the globe.

I would encourage you all to exploit the opportunities for interaction over the coming days, both physical and virtual. I hope that such networking will foster new ideas and collaborations that will help us to progress to earlier diagnosis, more effective treatments, and ultimately a cure for this most challenging of diseases.

I wish everyone an enjoyable and fruitful conference.

Noel Corrigan
Chair of Trustees – AMMF
noel@ammf.org.uk



Professor Juan Valle
University of Manchester
and The Christie



Professor Jesus Bañales
Biodonostia Institute, Spain

Dear Friends and Colleagues

We are delighted to welcome you all to this landmark conference which recognises 20 years since the inception of AMMF.

The 2022 anniversary event brings together an expert faculty and speakers who will deliver an engaging hybrid event that will explore the European and international aspects of cholangiocarcinoma (CCA).

On behalf of AMMF we will be hosting a world-renowned selection of speakers from across the globe who will speak of the challenges faced and advances made in our understanding and treatment of CCA over the past two decades and discuss the importance of accelerating the progress we are now seeing.

Our role as Co-Chairs is to facilitate and encourage the sharing of information amongst all attendees, both live and virtually, and throughout the meeting there will be several Q&A sessions aimed to ensure your questions are answered, and we look forward to your contributions.

During the meeting, we will also be taking the time to recognise those who have dedicated their lives and careers to improving the lives of CCA patients, and there will be a special 20 Years of AMMF: Awards of Recognition and Gratitude ceremony which will be presented by AMMF Trustees Noel Corrigan, Chair, and Harry Corrigan, Treasurer.



AMMF conference scenes...

We would also like to take the opportunity thank AstraZeneca, Incyte, Helsinn, Servier, Taiho Oncology, TransThera and Zymeworks without whose support this gathering and sharing of advances would not be possible

Finally, a special thank you to Helen Morement, CEO of AMMF, for her kind invitation to Co-Chair this important meeting and her ongoing commitment and dedication to those impacted by CCA.

We wish you all an enjoyable three days and safe onward travels.

Professor Juan Valle
University of Manchester and
The Christie, Manchester, UK

Professor Jesus Bañales
Biodonostia Institute
San Sebastian, Spain

Working throughout the UK and Europe, collaborating throughout the world for those with cholangiocarcinoma, AMMF is actively involved with many groups, organisations and ventures, national and international, including:



a member of
cancer52
the common voice
for less common cancers



When AMMF was founded and registered with the Charity Commission in 2002, it was the world's first charity dedicated solely to cholangiocarcinoma. It remains the UK's and Europe's only dedicated cholangiocarcinoma charity.

Over recent years an enormous and extremely worrying global increase in cholangiocarcinoma's incidence has been noted. The incidence appears to be increasing across all age groups, including younger people, and the cause of this ongoing increase is unknown. Much more research is desperately needed.

Throughout the last 20 years, AMMF has been, and remains, totally committed to tackling this devastating cancer on all fronts: providing information and support, campaigning to raise awareness, and encouraging and supporting specialised research teams, nationally and internationally in their work towards better diagnostic techniques and treatments and, ultimately a cure.

Dedicated to bringing about improvement for the cholangiocarcinoma patient, AMMF works closely with patients and their carers, clinicians, healthcare professionals, researchers, politicians and policy makers, as well as actively collaborating globally.

OUR MISSION

A world improved for the cholangiocarcinoma patient by the sharing of knowledge across the healthcare and research communities and with the family of affected people across the globe.

Registered charity no 1091915

TransThera 药捷安康

COMPANY WEBSITE

TransThera is dedicated to the patient-centered and integrated drug innovation and filling the gap of unequivocal unmet medical needs in cancer, inflammatory and cardiovascular disease.

TT-00420 the primary asset, has demonstrated promising efficacy in patients with relapsed or refractory cholangiocarcinoma (CCA) and acquired resistance to previous standard of care.

T R A N S T H E R A

March 2022 - Copyright: Juanmonino / E+ © Getty Images
- M-NL-UK-00997

An independent group committed to therapeutic progress to serve patient needs

Servier is a global pharmaceutical group governed by a Foundation. With a strong international presence in 150 countries and a total revenue of 4.7 billion euros in 2021, Servier employs 21,800 people worldwide. Servier is an independent group that invests over 20% of its brand-name revenue in Research and Development every year.

A leader in cardiology, the ambition of the Servier Group is to become a renowned and innovative player in oncology. Its growth is based on a sustained commitment to cardiovascular and metabolic diseases, oncology, neuroscience and immuno-inflammatory diseases. To promote access to healthcare for all, the Servier Group also offers a range of quality generic drugs covering most pathologies.

servier.co.uk

SERVIER

LAUNCHED!

AMMF EUROPEAN WEBSITE

Expanding the reach of AMMF across Europe!

AMMF THE CHOLANGIOCARCINOMA CHARITY

#AMMFEUWebsite

AMMF, the UK's only cholangiocarcinoma (CCA) charity, is committed to supporting not only those in the UK, but also European patients and carers living with CCA, through greater access to the information, resources and support they deserve.

Additional to AMMF's main, and comprehensive website, a new AMMF European CCA Website was launched on World CCA Day, in February 2022. This website will help to raise awareness and provide guidance and information on CCA in 8 European languages:

 Danish	 French	 Italian	 Portuguese
 Finnish	 German	 Polish	 Spanish

The new European CCA website will support patients and their carers/loved ones seeking information on all aspects of CCA across Europe, as well as helping healthcare practitioners, including clinical nurse specialists, to navigate information available for their patients with CCA.

Visit the New AMMF European CCA Website here: ammf-eu.org

AMMF thanks the following for their generous support for the European Cholangiocarcinoma Website:

Sponsors do not control nor influence the work of AMMF, nor the projects the charity supports.

PROOF Trial

NOW ENROLLING

Phase 3 Study

First-line Cholangiocarcinoma

- A multicenter, open-label, randomized, controlled study
- To evaluate the efficacy and safety of infiratinib vs. gemcitabine plus cisplatin in first-line treatment of patients with unresectable locally advanced or metastatic cholangiocarcinoma with **FGFR2* gene fusions/rearrangements**
- Participants are randomized (2:1) to receive oral infiratinib once daily for the first 3 weeks (21 days) of each 28-day cycle or gemcitabine plus cisplatin given on days 1 and 8 of a 21-day treatment cycle
 - If an individual's **FGFR2** status is unknown, they will be offered molecular testing as part of the prescreening procedures
 - One cycle of gemcitabine-based chemotherapy is allowed prior to randomization
- Primary endpoint is progression-free survival (PFS), as assessed by blinded independent central review (BICR)
- Scan for additional information on the study or to find a site near you:

Investigational Drug

Infiratinib—oral, once daily

Once daily



3 weeks on,
1 week off

Comparator

Intravenous gemcitabine plus cisplatin



NCT03773302

*Fibroblast Growth Factor Receptor 2

The safety and efficacy of infiratinib have not been demonstrated for the uses described here.

Infiratinib is developed globally by Helsinn Healthcare S.A. in all fields of use except for skeletal dysplasias and except in the following territories: China, Hong Kong and Macau.

© 2022 Helsinn Healthcare S.A. All rights reserved.

HELS-0025



WORLD CHOLANGIOCARCINOMA DAY

AMMF strongly believes collaboration is the way towards progress and is proud to have instigated the first World Cholangiocarcinoma Day in 2016.

This international venture, founded on the ethos of working with a nationally neutral but globally inclusive voice, has continued to grow in influence as it works to raise awareness and to address the many unmet needs of cholangiocarcinoma patients throughout the world.

www.globalccaalliance.com/en/world-cca-day

GLOBAL CHOLANGIOCARCINOMA ALLIANCE

Leading cholangiocarcinoma specialists and patient advocates from around the world met at an international workshop led by AMMF in London in 2018. There they shared the vision to make significant and increased global awareness, and progress for cholangiocarcinoma's diagnosis, treatment, cure, and eventual eradication – and the Global Cholangiocarcinoma Alliance began.

Launched on World CCA Day 2019, The Global Cholangiocarcinoma Alliance, led by an international steering committee of CCA specialists and patient advocates, is now working towards greater global collaborations with a comprehensive portfolio of initiatives to provide the worldwide cholangiocarcinoma community with a platform to build links and exchange knowledge to deliver the shared vision.

www.globalccaalliance.com



Global
Cholangiocarcinoma
Alliance

“This multidisciplinary group is much-needed in tackling cholangiocarcinoma. It's not something one organisation can do; it needs gifted people from a variety of backgrounds to make a difference.”

*Professor Shabid A Khan,
Imperial College London*



www.ammf.org.uk

PRESENTERS



Helen Morement

Founder and CEO

AMMF – The Cholangiocarcinoma Charity



Noel Corrigan

Chair of Trustees

AMMF – The Cholangiocarcinoma Charity



Margaret Griffin

Clinical Nurse Specialist

Aintree Hospital, Liverpool



Dr Rachel Greig

Associate Director

Therapy Lead – Cholangiocarcinoma
Incyte Biosciences UK Ltd



Harry Corrigan

Treasurer, Trustee

AMMF – The Cholangiocarcinoma Charity



Professor Juan Valle

Professor of Medical Oncology

University of Manchester and
The Christie



Professor Shahid A Khan

Professor of Practice (Hepatology)

Imperial College NHS Trust,
Faculty of Medicine, Imperial College London



Dr Sophie Jose

Senior Health Data Analyst

Health Data Insight CIC,
Cambridge



Professor Jesus Bañales

Head of the Liver Diseases Group

Biodonostia Research Institute, Spain

Professor of Sciences

University of Navarra, Spain

Assistant Professor Medicine/Sciences

Mayo Clinic, USA and University of
Area Andina, Colombia



Louise Jones

Clinical Nurse Specialist

Aintree Hospital, Liverpool



Andy Spavins

Patient Presenter



Mr Hassan Z Malik

Consultant General and

Hepatobiliary Surgeon

Clinical Director for Digestive Surgery,
Aintree University Hospital NHS
Foundation Trust, Liverpool

See more presenters overleaf

PRESENTERS

PRESENTERS



Mr Raj Prasad

Consultant Surgeon

Hepatobiliary and Transplant Unit
Leeds Teaching Hospitals



Professor Maria A. Hawkins

Professor in Radiation Oncology


University College Hospital,
London



Dr Vincenzo Cardinale

Associate Professor of Gastroenterology

Department of Medical-Surgical Sciences
and Biotechnologies, University of Sapienza,
Rome, Italy



Dr Cindy Neuzillet

Head of GI Oncology

Currie Institute, Saint Cloud,
France



Professor John Bridgewater

Consultant Medical Oncologist

University College Hospital London

Clinical Researcher

UCL Cancer Institute, London



Dr Christopher Wadsworth

Consultant Gastroenterologist

and HPB Physician

Imperial College Healthcare NHS Trust



Dr Heinz-Josef Klumpen

Medical Oncologist

Amsterdam University Medical Center,
University of Amsterdam, The Netherlands



Professor Ross Andrews

Professor of Parasitology (Hon)

Imperial College London and
Khon Kaen University, Thailand



Professor Robert Goldin

Professor of Liver and GI Pathology

Faculty of Medicine, Department of
Metabolism, Digestion and Reproduction,
Imperial College London

Ludwig Institute of Cancer Research
University of Oxford



Andrea Sheardown

Patient Presenter



Professor Narong Khuntikeo

Liver Surgeon, Faculty of Medicine

Khon Kaen University, Director of The Liver
Fluke and Cholangiocarcinoma Research Centre,
Chairman of CASCAP (The Cholangiocarcinoma
Screening and Care Program), Chair of
The Cholangiocarcinoma Foundation of
Thailand, Khon Kaen, Thailand



Dr Shijie Cai

Senior Research Associate

Nuffield Division of Clinical Laboratory
Sciences, University of Oxford

See more presenters overleaf

PRESENTERS

PRESENTERS



Professor Kevin Gaston

Professor of Cancer Services


School of Medicine and Biodiscovery Institute
University of Nottingham



Dr Isioma Egbuniwe

*NIHR Clinical Lecturer/
Assistant Professor in Pathology*

Academic Unit of Translational Medical Sciences
University of Nottingham



Dr Ed Jarman

Postdoctoral Research Fellow

The MRC Human Genetics Unit
Institute of Genetics and Cancer
University of Edinburgh



Gemma Owen


DPhil Student in Medical Sciences

Nuffield Division of Clinical Laboratory Sciences
Radcliffe Department of Medicine
University of Oxford




Professor Sheela Jayaraman

*Professor of Cancer Biology and Gene
Regulation, Co-director and Research Lead*
Centre for Cancer Sciences, Biodiscovery Institute
University of Nottingham



Mr Timothy Gilbert

Surgical Registrar and HPB Research Fellow
Liverpool University Hospitals NHS FT/
University of Liverpool



Dr Stephen Griffin

Associate Professor
Leeds Institute of Medical Research
University of Leeds



Dr Pedro Rodrigues

Basic and Translational Scientist
Specialized in the study of Cholangiocarcinoma
Liver Diseases Group
Biodonostia Health Research Institute, Spain



Dr Laura Randle

Senior Lecturer in Biomolecular Science
School of Pharmacy and Biomolecular Sciences,
Liverpool John Moores University



Dr Luke Boulter

*Luke Boulter Research Group
Principal Investigator*
MRC Institute of Genetics and Molecular
Medicine, MRC Human Genetics Unit,
The University of Edinburgh



Alex Kilvington

Postgraduate Researcher
University of Leeds



Dr Shirin E Khorsandi

King's College Hospital, London



Dr Chiara Braconi
Clinician Scientist

Institute of Cancer Sciences
University of Glasgow
*Honorary Consultant
Medical Oncologist*
Beatson West of Scotland
Cancer Centre

PRESENTERS

DAY ONE – Wednesday 11th May

TIME	MIN	TOPIC	SPEAKER
15.00 – 15.30	30	Early arrivals – Informal meet for introductions, tea and cake	AMMF Team <i>Pre-function Room</i>
FOR PATIENTS & CARERS			
15.30 – 15.35	5	Introduction to the afternoon sessions	Helen Morement <i>CEO – AMMF</i>
15.30 – 16.15	40	Meet the Clinical Nurse Specialist (CNS) Q&A	Louise Jones and Margaret Griffin <i>Aintree Hospital, Liverpool</i>
16.15 – 16.40	25	Introducing Molecular Profiling Q&A	Dr Rachel Greig <i>Associate Director, Therapy Area Lead – Cholangiocarcinoma Incyte Biosciences UK Ltd</i>
FOR CLINICAL NURSE SPECIALISTS			
16.40 – 17.30	50	How AMMF can support the Clinical Nurse Specialist Q&A	Helen Morement <i>CEO – AMMF</i> Dr Rachel Greig <i>Associate Director, Therapy Area Lead – Cholangiocarcinoma Incyte Biosciences UK Ltd</i>
17.30 – 18.30		<i>Break and Networking</i>	<i>All</i>
18.30 onwards		<i>Meet and Mingle Buffet</i>	<i>All</i>
20.00 – 21.00	60	AMMF Clinical/Medical Advisors Board Meeting	Invitation only <i>Room 4</i>

*Please note: Poster + Exhibitor Halls are intended for HCPs only.

DAY TWO – Thursday, 12th May – Morning Session

TIME	MIN	TOPIC	SPEAKER
08.00 – 08.45	45	<i>Registration and Coffee</i>	
08.45 – 09.00	15	Co-chairs' Welcome	Professor Juan Valle <i>University of Manchester and The Christie</i> Professor Jesus Bañales <i>Biodonostia Institute, Spain</i>
09.00 – 09.15	15	Reflecting on 20 years of AMMF: 2002 – 2022	Helen Morement <i>CEO – AMMF</i>
09.15 – 09.35	20	CCA Overview: How far have we come?	Professor Shahid A Khan <i>Imperial College London</i>
09.35 – 09.55	20	The AMMF CCA Data Project	Dr Sophie Jose <i>Senior Health Data Analyst – Health Data Insight CIC</i>
09.55 – 10.05	10	<i>Question Time</i>	<i>Panel</i>
10.05 – 10.25	20	<i>Coffee and Networking</i>	<i>All</i>
10.25 – 10.40	15	The Patient Perspective The Human Impact – In Memory of Mark Spavins	Andrew Spavins
A MATURING TREATMENT LANDSCAPE <i>Chaired by Professor Juan Valle</i>			
10.40 – 10.45	05	Session Introduction	Professor Juan Valle <i>University of Manchester and The Christie</i>
10.45 – 11.05	20	Surgery for CCA: Past, Present and Future	Mr Hassan Malik <i>Aintree Hospital, Liverpool</i>
11.05 – 11.25	20	Transplantation for CCA: Where we are now	Mr Raj Prasad <i>Leeds Teaching Hospitals</i>

Times shown are GMT. For CET +1 hour.

Programme continued overleaf

DAY TWO – Thursday, 12th May – Morning Session (continued)

TIME	MIN	TOPIC	SPEAKER
11.25 – 11.45	20	Radiotherapy: Does it have a place in CCA?	Professor Maria Hawkins <i>University College London</i>
11.45 – 12.05	20	The ABC Trials: What have they taught us?	Professor John Bridgewater <i>University College London</i>
12.05 – 12.20	15	<i>Question Time</i>	<i>Panel</i>
12.20 – 12.35	15	20 years of AMMF: Awards of Recognition and Gratitude	AMMF Trustees: <i>Noel Corrigan, Chair</i> <i>Harry Corrigan, Treasurer</i>
12.35 – 13.45	70	<i>Lunch and Networking</i>	<i>All</i>
HERITAGE PRESENTATIONS Room 10			
12.45 – 13.05	20	AstraZeneca: Aiming to lead a revolution in oncology to redefine cancer care	AstraZeneca <i>Healthcare Professionals only</i>
13.20 – 13.30	10	We see CCA	Incyte Biosciences International <i>All delegates</i>
PRESENTATION FOR PATIENTS & CARERS Room 19			
13.00 – 13.20	20	Nutrition for the CCA Patient	Video presentation by Glenda O'Connor <i>Senior Specialist Dietitian,</i> <i>Wellington Hospital, London</i>

*Please note: Poster + Exhibitor Halls are intended for HCPs only.

DAY TWO – Thursday, 12th May – Afternoon Session

TIME	MIN	TOPIC	SPEAKER
A MATURING TREATMENT LANDSCAPE (continued) <i>Chaired by Professor Juan Valle</i>			
13.45 – 14.05	20	Endoscopy and Stenting	Dr Christopher Wadsworth <i>Imperial College London</i>
14.05 – 14.25	20	Pathology: CCA under the microscope	Professor Robert Goldin <i>Imperial College London</i>
14.25 – 14.40	15	<i>Question Time</i>	<i>Panel</i>
14.40 – 14.55	15	The Patient Perspective The climb continues ...	Andrea Sheardown
INTERNATIONAL ASPECTS OF CCA PART 1 <i>Chaired by Professor Jesus Bañales</i>			
14.55 – 15.05	10	Session Introduction	Professor Jesus Bañales <i>Biodonostia Institute, Spain</i>
15.05 – 15.25	20	The work of ENS-CCA, & the EURO-CHOLANGIO-NET COST Action Project	Professor Vincenzo Cardinale <i>Sapienza University, Rome</i>
15.25 – 15.45	20	The view from France	Dr Cindy Neuzillet <i>Curie Institute Saint Cloud</i> <i>Paris, France</i>
15.45 – 16.05	20	The view from The Netherlands	Dr Heinz-Josef Klumpen <i>Amsterdam Medical Center,</i> <i>University of Amsterdam,</i> <i>The Netherlands</i>
16.05 – 16.20	15	<i>Question Time</i>	<i>Panel</i>
16.20 – 16.35	15	<i>Tea and Networking</i>	<i>All</i>

Times shown are GMT. For CET +1 hour.

Programme continued overleaf

DAY TWO – Thursday, 12th May – Afternoon Session (continued)

TIME	MIN	TOPIC	SPEAKER
INTERNATIONAL ASPECTS OF CCA PART 2 <i>Chaired by Professor Jesus Bañales</i>			
16.35 – 16.45	10	Session Introduction	Professor Jesus Bañales <i>Biodonostia Institute, Spain</i>
16.45 – 17.05	20	The Professor Puangrat Yongvanit Memorial Lecture	Professor Ross Andrews <i>Imperial College London, Khon Kaen University, Thailand</i>
17.05 – 17.25	20	The view from South East Asia	Professor Narong Khuntikeo <i>Khon Kaen University, Thailand</i>
17.25 – 17.45	20	Review of Molecular Genetics of Intrahepatic Cholangiocarcinoma in China	Dr Shijie Cai <i>University of Oxford</i>
17.45 – 18.00	15	Question Time	Panel
18.00 – 18.10	10	Co-chairs' Closing remarks	Professor Juan Valle <i>University of Manchester and The Christie</i> Professor Jesus Bañales <i>Biodonostia Institute, Spain</i>
18.10 – 19.30	80	Networking	All
18.30 – 19.15	45	Global CCA Alliance	Invitation only <i>Room 4</i>
19.30 – 21.30	120	Buffet Dinner	All

*Please note: Poster + Exhibitor Halls are intended for HCPs only.

DAY THREE – Friday, 13th May – Morning Session

TIME	MIN	TOPIC	SPEAKER
08.15 – 09.00	45	<i>Welcome Coffee</i>	
08.00 – 08.50	50	Cholangiocarcinoma-UK Committee Meeting	Invitation only <i>Room 4</i>
09.00 – 09.15	15	Co-chairs' Welcome to Day Three	Professor Juan Valle <i>University of Manchester and The Christie</i> Professor Jesus Bañales <i>Biodonostia Institute, Spain</i>
SCIENTIFIC PRESENTATIONS: AMMF Supported Research and Introducing Hubs of Expertise			
09.15 – 09.20	05	Session Introduction	Professor Juan Valle <i>University of Manchester and The Christie</i>
09.20 – 10.20	60 (15)	Nottingham – Introduction to the CCA work at Nottingham	Professor Kevin Gaston <i>University of Nottingham</i>
	(15)	AMMF supported research: “Investigating the role of Interleukin 17 (IL-17) in tumour lymphangiogenesis in CCA”	Dr Isioma Egbuniwe <i>University of Nottingham</i>
	(15)	“Identifying new drug combinations for the <i>in vitro</i> inhibition of cholangiocarcinoma cell growth”	Professor Sheela Jayaraman <i>University of Nottingham</i>
	(15)	Question Time	Nottingham Panel
10.20 – 10.40	20	Coffee and Networking	All

Times shown are GMT. For CET +1 hour.

Programme continued overleaf

DAY THREE – Friday, 13th May – Morning Session (continued)

TIME	MIN	TOPIC	SPEAKER
10.40 – 11.40	60 (15)	Liverpool – Introduction to the CCA work at Liverpool: A triumvirate of clinical service development, training and research, defining a centre of expertise	Mr Hassan Malik <i>Aintree University Hospital</i>
	(15)	AMMF supported research: “Identification of actionable targets in peri-hilar CCA using whole exome sequencing”	Dr Timothy Gilbert <i>Liverpool University Hospitals/ University of Liverpool</i>
	(15)	“Developing an ex-vivo tissue model of CCA using precision”	Dr Laura Randle <i>Liverpool John Moores University</i>
	(15)	<i>Question Time</i>	<i>Liverpool Panel</i>
11.40 – 12.40	60 (10)	Edinburgh and Glasgow, Scotland – Introduction and cholangiocarcinoma in Scotland – combining efforts between Edinburgh and Glasgow	Dr Luke Boulter <i>University of Edinburgh</i>
	(20)	AMMF supported research: “Using patient-led genetics to define new therapeutic targets in intrahepatic cholangiocarcinoma”	Dr Luke Boulter <i>University of Edinburgh</i>
	(15)	“Modelling the earliest moments of CCA formation at the interface of liver damage and genetic mutation.”	Dr Ed Jarman <i>University of Edinburgh</i>
	(15)	<i>Question Time</i>	<i>Edinburgh Panel</i>

*Please note: Poster + Exhibitor Halls are intended for HCPs only.

TIME	MIN	TOPIC	SPEAKER
12.40 – 13.50	70	<i>Lunch and Networking</i>	<i>All</i>
HERITAGE PRESENTATIONS Room 10			
12.50 – 13.10	20	AstraZeneca: Aiming to lead a revolution in oncology to redefine cancer care	AstraZeneca <i>Healthcare Professionals only</i>
13.25 – 13.35	10	We see CCA	Incyte Biosciences International <i>All delegates</i>

DAY THREE – Friday, 13th May – Afternoon Session

TIME	MIN	TOPIC	SPEAKER
AMMF Supported Research (continued) Chaired by Professor Jesus Bañales			
13.50 – 14.10	20	“The role of normal cholangiocytes in regulating cholangiocarcinoma cells during co-culture”	Gemma Owen <i>University of Oxford</i>
14.10 – 14.30	20	“Virus-driven intrahepatic CCA”	Dr Stephen Griffin <i>University of Leeds</i>
14.30 – 14.50	20	“Role of the transcription factor KLF5 in the etiopathogenesis of CCA: new diagnostic prognostic and therapeutic strategy”	Dr Pedro Rodrigues <i>Biodonostia Institute, Spain</i>
14.50 – 15.05	15	<i>Question Time</i>	<i>Research Panel</i>
15.05 – 15.20	15	<i>Tea and Networking</i>	<i>All</i>

Times shown are GMT. For CET +1 hour.

Programme continued overleaf

Proud Supporter of the AMMF




United in sending patients home, disease free

Zymeworks is dedicated to making targeted therapies that meaningfully improve the lives of people with cancer. Our HER2-targeted antibody zanidatamab is being evaluated in pivotal clinical trials in biliary tract cancer and gastric cancer.

WWW.ZYMEWORKS.COM
TWITTER @ZYMEWORKSINC



Making the human connection.

Commitment Innovation Care

At Taiho Oncology, our mission is to improve the lives of patients with cancer, their families, and their caregivers. Taiho continues to deliver innovative products to the U.S. and global marketplace.

The oncology patient, and their support systems, are at the center of our every activity.



© TAIHO ONCOLOGY, INC. All rights reserved. 03/2022 TOI-PM-US-0540 v1

DAY THREE – Friday, 13th May – Afternoon Session (continued)

TIME	MIN	TOPIC	SPEAKER
LOOKING TO THE FUTURE <i>Chaired by Professor Juan Valle</i>			
15.20 – 15.35	15	The way ahead...	Helen Morement CEO – AMMF
15.35 – 15.55	20	Artificial Intelligence Guide to treatment and Q&A	Dr Shirin E Khorsandi <i>King's College Hospital, London</i>
15.55 – 16.35	40	Organoid and Animal Models: Seminar and Q&A	Dr Chiara Braconi <i>University of Glasgow</i> Dr Luke Boulter <i>University of Edinburgh</i>
16.35 – 16.50	15	<i>Conference Closing</i>	<i>Co-chairs:</i> Professor Juan Valle <i>University of Manchester and The Christie</i> Professor Jesus Bañales <i>Biodonostia Institute, Spain</i> And Helen Morement CEO – AMMF

**Please note: Poster + Exhibitor Halls are intended for HCPs only.
Times shown are GMT. For CET +1 hour.*

Join us again next year

AMMF 2023 European Cholangiocarcinoma Conference

10–12 May 2023 (tbc)

Venue: Radisson Blu Hotel,
Stansted Airport, UK




POSTER PRESENTATIONS 2022

The following posters can be viewed in the Conference Poster Hall, where each of the authors can be heard presenting their work.

1 Roseanna C Wheatley, University of Manchester and The Christie NHS Foundation Trust, Manchester

EMBRACER study: Evaluation of the microbiome in patients receiving systemic anti-cancer treatment for biliary tract cancer

2 Raffaella Casolino, University of Glasgow

Audit of the centralized oncology clinic for biliary tract cancers in the West of Scotland

3 Raffaella Casolino, University of Glasgow and University of Verona

Bridging the equity gap in patient education: the biliary cancer Babel project

4 Ben Johnson, Medscape Oncology, Amsterdam

Integration of molecular guided therapy for the treatment of advanced cholangiocarcinoma: continuing-online education improves competence and confidence of physicians

5 Margherita Rimini, Vita-Salute San Raffaele University, Milan

Genomic analysis of cholangiocarcinoma identifies distinct IDH-mutated clusters

6 Margherita Rimini, Vita-Salute San Raffaele University, Milan

IDH1 in intrahepatic cholangiocarcinoma: a comparative genomic analysis and clinical impact

7 Margherita Rimini, Vita-Salute San Raffaele University, Milan

Gene mutational profile of BRCAness and clinical implication in predicting response to platinum-based chemotherapy in patients with intrahepatic-cholangiocarcinoma

8 Teresa Perra, University of Sassari

Intraoperative assessment of tissue oxygenation for prediction of bile leakage in liver resection with hepaticojunostomy for cholangiocarcinoma

POSTER PRESENTATIONS 2022

9 Angela Lamarca, The Christie NHS Foundation Trust, Manchester

Natural history of patients with advanced cholangiocarcinoma (CCA) and *FGFR2* gene fusions/rearrangements

10 Angela Lamarca, The Christie NHS Foundation Trust, Manchester

Broadening the therapeutic horizon of cholangiocarcinoma through molecular-targeted treatments/precision medicine

11 Salvador Escorza Calzada, Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán, Mexico City

Intrahepatic cholangiocarcinoma associated with hypercalcemia secondary to 1,25 dihydroxyvitamin D in a young adult

12 Francesco Amato, University of Glasgow

Liquid biopsy in biliary tract cancer patients undergoing first line combination chemotherapy

13 Megan Illingworth, Foundation for Liver Research and King's College, London

Transcriptomic profiling identifies ribosomal proteins as novel genes of interest in primary sclerosing cholangitis associated cholangiocarcinoma

14 Vera Cappelletti, Fondazione IRCCS Istituto Nazionale dei Tumori di Milano, Milan

Identification of distinct biological subclasses of intrahepatic and extrahepatic cholangiocarcinoma by comprehensive transcriptomic analysis

15 Juan Valle, University of Manchester and the Christie NHS Foundation Trust

A Phase 3 randomised, double-blind, placebo-controlled study of durvalumab in combination with gemcitabine plus cisplatin (GemCis) in patients with advanced biliary tract cancer (BTC): TOPAZ-1

Please note: the Poster Hall is intended for HCPs only.



CHOLANGIOCARCINOMA-UK

Instigated in 2018, Cholangiocarcinoma-UK is a group affiliated to the British Association for the Study of the Liver (BASL).



This is a multi-disciplinary group of clinicians, scientists and patient advocates whose purpose is to facilitate collaborative research, enhance service development and raise the awareness of cholangiocarcinoma.

The specific aims of Cholangiocarcinoma-UK are to:

- Facilitate basic science and clinical research as well as sample collection, including for biomarker development
- Improve the pathway to collaborative clinical trials and opportunities for research funding
- Update national guidelines and advise on policy and best practice
- Optimise and standardise clinical management across the country
- Monitor epidemiological trends accurately

Current members of the Cholangiocarcinoma-UK Steering Committee are:

Chair	Professor Shahid Khan*	Imperial College, London
Secretary	Professor Derek Manas*	Freeman Hospital, Newcastle upon Tyne
Patient advocate	Helen Morement*	AMMF – The Cholangiocarcinoma Charity
Basic science representatives	Professor David Bates	University of Nottingham
	Dr Luke Boulter	MRC Human Genetics Unit, Edinburgh
	Dr Chiara Braconi	University of Glasgow
	Dr Sheela Jayaraman	University of Birmingham
Endoscopy representative	Professor Steve Pereira	University College/Royal Free Hospital, London
Hepatology representative	Dr Simon Rushbrook	Norfolk & Norwich University Hospitals
Clinical oncology representative	Professor Maria Hawkins	University College, London
Medical oncology representatives	Professor John Bridgewater*	University College, London
	Professor Juan Valle	Christie NHS Foundation Trust/ University of Manchester
Pathology representative	Dr Tim Kendall	University of Edinburgh/ Royal Infirmary Edinburgh
Surgery representatives	Professor Brian Davidson	Royal Free Hospital, London
	Professor Nigel Heaton	King's College Hospital, London
	Mr Hassan Malik	Aintree University Hospital
Trainee representatives	Dr Pilar Acedo	University College, London
	Dr Leonard Marc Quinn	University of Liverpool

* Also members of the CCA-UK Executive Committee

www.basl.org.uk/index.cfm/content/page/cid/28

AMMF thanks the following for their generous support for the European Cholangiocarcinoma Conference 2022:

PLATINUM SPONSORS



SILVER SPONSOR



BRONZE SPONSORS



Sponsors do not control nor influence the work of AMMF, nor the projects the charity supports.



AMMF – The UK’s only cholangiocarcinoma charity

Working throughout the UK
and Europe, collaborating
throughout the world for those
with cholangiocarcinoma

www.ammf.org.uk
www.ammf-eu.org

Enterprise House
Bassingbourn Road, Stansted
Essex CM24 1QW. UK

Tel: +44 (0)1279 661479
Email: info@ammf.org.uk



Follow us on Facebook, Twitter, Instagram and Linked In – charityAMMF